The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that ...

Silexion Therapeutics (SLXN) announced an expanded development plan for its next-generation siRNA candidate, SIL204. This strategy integrates ...

The firm said its next-generation siRNA candidate showed in preclinical studies that it could reduce tumor growth and metastatic spread.

Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration ...

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...

Silexion Therapeutics completes development plan for next-generation siRNA candidate SIL204; plans to present at 2025 NeauxCancer Conference: Grand Cayman, Cayman Islands Tuesday, ...

An institutional investor recently bought a new position in Silexion Therapeutics stock. Wildcat Capital Management LLC bought a new position in shares of Silexion Therapeutics Corp (NASDAQ ...

Silexion Therapeutics Corp. announced promising results from preclinical studies of its RNA interference therapy, SIL204, for KRAS-driven pancreatic cancer. The research, conducted in orthotopic ...

Silexion Therapeutics approaches a potential key milestone with upcoming orthotopic pancreatic cancer model data, which, if positive, could validate systemic efficacy against metastatic disease ...

Convertible Series A Preferred Shares (NIS 0.09 par value, 0 and 56,667 shares authorized as of December 31, 2024 and 2023, 0 and 43,121 shares issued and outstanding as of December 31, 2024 and ...

Grand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA ...